Buscopan API Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export

Buscopan API Market structural outlook and growth narrative

The Buscopan API Market is entering a phase of steady, data-backed expansion as demand for hyoscine butylbromide-based antispasmodics climbs across both developed and emerging healthcare systems. According to Datavagyanik, the core Hyoscine-N-Butyl Bromide backbone of the Buscopan API Market was valued at around US$ 56.8 million in 2023 on the API-equivalent basis and is projected to approach nearly US$ 88 million by 2032, translating into a sustained CAGR of close to 5% over 2024–2032. This Buscopan API Market trajectory is closely aligned with broader antispasmodic drug revenues, where segmental analyses show global antispasmodics growing at roughly 6–9% annually through 2030, indicating that the Buscopan API Market is firmly embedded in one of the more resilient therapeutic categories in gastrointestinal care.

Epidemiological tailwinds in Buscopan API Market

A primary driver for the Buscopan API Market is the rising prevalence of functional gastrointestinal disorders, particularly irritable bowel syndrome (IBS) and recurrent abdominal cramps in aging and urbanizing populations. For instance, global IBS prevalence is increasingly recognized as under-reported, and large-scale surveys in major markets have documented substantial symptom burden, directly supporting higher prescribing of antispasmodic brands such as Buscopan and, in turn, underpinning growth in the Buscopan API Market. According to Datavagyanik, the wider hyoscine and antispasmodic drug universe has been sized at roughly US$ 398 million in 2022 for hyoscine overall and more than US$ 14 billion for total antispasmodic drugs by 2025, and even low-to-mid single-digit volume growth in this pool translates into meaningful incremental demand for the Buscopan API Market.

Therapeutic positioning of Buscopan API Market in abdominal pain and IBS

The clinical profile of hyoscine butylbromide, the core of the Buscopan API Market, is a central factor behind its sustained demand across multiple care settings. For example, Buscopan is recognized for delivering rapid relief of stomach cramps and IBS-related abdominal pain, often within about 15 minutes, which makes prescribers and patients favor it over slower-acting alternatives and thereby supports recurring API off-take. Moreover, Datavagyanik notes that the molecule’s inability to cross the blood–brain barrier significantly limits central nervous system adverse effects, and real-world evidence showing that around 99% of patients report no CNS side effects during long-term use reinforces confidence in the Buscopan API Market as a safe, chronic-use antispasmodic option. This safety–efficacy balance, combined with a well-established brand franchise, positions the Buscopan API Market as a reference standard in antispasmodic therapy, especially in Europe and other mature pharmaceutical markets.

Formulation trends shaping Buscopan API Market demand

Formulation innovation is another crucial trend within the Buscopan API Market, particularly the shift toward granular and patient-friendly oral dosage forms. For instance, granular Hyoscine-N-Butyl Bromide has been assessed to grow faster than other forms, with Datavagyanik indicating a CAGR of nearly 5.9% over 2024–2032, outpacing the overall API base; this higher growth directly feeds into differentiated demand for specific Buscopan API Market grades tailored to advanced granulation technologies. Since approximately 60% of small-molecule drugs are delivered orally and oral formulations account for roughly 90% of all human pharmaceutical products, formulation preferences structurally favor APIs such as Buscopan that are optimized for tablets, capsules, and oral solutions. Consequently, the Buscopan API Market increasingly benefits from customers seeking high-flow, high-compressibility API qualities that can support modern continuous manufacturing and high-speed tableting.

Antispasmodics super-cycle and Buscopan API Market

The Buscopan API Market also rides on the broader “antispasmodics super-cycle,” where rising diagnosis of gastrointestinal and genitourinary spasmodic conditions drives sustained brand and generic uptake. For example, the antispasmodics drugs market has been estimated at about US$ 4.5–15 billion in the early-to-mid 2020s and is projected to grow at 6–9% CAGR toward 2030, supported by factors such as an aging population, better diagnostic pathways, and expanding access to specialist gastroenterology care. Within this context, the Buscopan API Market benefits disproportionately from its entrenched position in physician prescribing habits and over-the-counter segments in Europe, Latin America, and parts of Asia, allowing Buscopan API manufacturers to command stable volumes even when competitive generics enter the market. As new antispasmodic combinations and fixed-dose regimens are developed, Datavagyanik expects the Buscopan API Market to see incremental opportunities in co-formulations targeting IBS, dysmenorrhea, and biliary colic, further diversifying the demand base.

Regional expansion patterns in Buscopan API Market

Regionally, the Buscopan API Market growth profile is not uniform, with Europe currently holding the largest share and Asia Pacific emerging as the fastest-growing demand center. For instance, Datavagyanik highlights that Europe accounts for about one-third of the Hyoscine-N-Butyl Bromide value pool, supported by long-standing use of Buscopan in both prescription and OTC segments, while the Asia Pacific share is expected to rise by roughly 2 percentage points by 2032 on the back of rising healthcare expenditure and broader pharmacy penetration. In parallel, the Buscopan API Market is seeing intensified activity in Latin America and the Middle East & Africa, where expanding retail pharmacy networks and growing middle-class populations are accelerating the uptake of branded and generic antispasmodics. These regional shifts imply that Buscopan API Market Size is gradually rebalancing from a Europe-centric base to a more multipolar configuration, with Asia Pacific and emerging markets accounting for a larger share of incremental volume growth through 2030.

Manufacturing landscape and capacity trends in Buscopan API Market

On the supply side, the Buscopan API Market is characterized by a concentrated but globally distributed base of manufacturers and traders with strong regulatory credentials. For example, platforms such as PharmaCompass list around 20 distinct entities associated with Buscopan API and related finished formulations, including players like Alchem International, Aspen API, LGM Pharma, Transo-Pharm, Fine Chemicals Corporation, and several Asian producers such as Zhejiang Ausun Pharmaceutical, many of which hold USDMF, CEP, JDMF, and other major regulatory filings. Datavagyanik observes that this regulatory depth provides assurance of continuity of supply for global brands and large generics, while simultaneously intensifying competition in the Buscopan API Market on price and quality differentiation. Additionally, as more Buscopan API Market participants invest in EU-GMP and FDA-inspected facilities, the barrier to entry for new suppliers rises, consolidating share among established manufacturers that can meet stringent quality, traceability, and sustainability benchmarks.

Quality, compliance and pricing dynamics in Buscopan API Market

Quality and compliance trends are increasingly shaping pricing and contract structures within the Buscopan API Market. For instance, the recent enforcement actions by European competition authorities involving an API supplier underscore that regulators are paying closer attention to pricing behavior and potential collusion in niche API categories, which pushes Buscopan API Market participants toward greater transparency and robust compliance frameworks. According to Datavagyanik, this regulatory scrutiny, combined with the cost of maintaining multi-jurisdictional DMFs and GMP certifications, is likely to keep Buscopan API Market prices firm, with limited room for aggressive undercutting except from highly efficient Asian manufacturers. At the same time, customers—especially leading originator companies and large generics—are increasingly using total cost-of-ownership models that reward stable quality, on-time delivery, and risk diversification, indirectly supporting premium pricing for top-tier Buscopan API Market suppliers.

Buscopan API Market Size and downstream brand performance

Downstream brand performance is a critical proxy for Buscopan API Market Size and long-term visibility. Buscopan, marketed primarily by Boehringer Ingelheim, continues to be a cornerstone product in the antispasmodic segment, with strong brand recognition and physician preference in Europe, Latin America, and parts of Asia, ensuring stable base demand for the associated API. For example, Datavagyanik notes that Buscopan’s leading role in the Hyoscine-N-Butyl Bromide space, supported by ongoing marketing, lifecycle management, and geographic expansion, effectively anchors Buscopan API Market Size and cushions it from short-term fluctuations in generic pricing cycles. As originator and generic versions penetrate new indications and OTC channels, the Buscopan API Market can leverage incremental volume from line extensions, pediatric formulations, and combination therapies without significant changes to the underlying synthesis route.

Demand diversification and future outlook for Buscopan API Market

Looking ahead, the Buscopan API Market is expected to diversify its demand base across several structural growth vectors, including demographic aging, urban lifestyle shifts, and broader access to gastroenterology care. For instance, the global geriatric population is expanding rapidly, and elderly patients exhibit higher rates of chronic abdominal discomfort, IBS, and spastic conditions, which typically require long-term antispasmodic management and thereby support recurring API procurement cycles in the Buscopan API Market. Additionally, Datavagyanik anticipates that rising healthcare spending in emerging economies, combined with the proliferation of online and retail pharmacies, will make abdominal pain treatments more accessible, translating into steady mid-single-digit annual volume growth for the Buscopan API Market over the next decade. As manufacturers continue to invest in capacity, formulation support, and regulatory filings, the Buscopan API Market is poised to maintain its relevance as a specialized but steadily expanding niche within the global gastrointestinal therapeutics value chain.

“Track Country-wise Buscopan API Production and Demand through our Buscopan API Production Database”

• • • Buscopan API production database for 22+ countries worldwide
    • Buscopan API sales volume for 22+ countries
    • Country-wise Buscopan API production capacity and production plant mapping, production capacity utilization for 20+ manufacturers
    • Buscopan API production plants and production plant capacity analysis for top manufacturers

Regional demand dynamics in Buscopan API Market

The Buscopan API Market is geographically concentrated in Europe today, but demand is rapidly broadening across Asia Pacific and other emerging clusters. Datavagyanik estimates that Europe currently captures around 34% of the underlying hyoscine butylbromide value pool that anchors the Buscopan API Market, supported by entrenched usage of Buscopan for abdominal pain, IBS, and genitourinary spasms in both prescription and OTC channels. For instance, abdominal pain, oesophageal spasms, renal colic, bladder spasms, and IBS together account for a rising share of outpatient consultations, and each of these indications routinely features Buscopan in treatment algorithms, ensuring a stable offtake pattern in the Buscopan API Market.

Asia Pacific growth engine for Buscopan API Market

Asia Pacific is emerging as the fastest-growing demand node within the Buscopan API Market, reflecting both epidemiological and economic shifts. Datavagyanik notes that East Asia alone is projected to command about 24.6% of the global hyoscine N‑butyl bromide market by 2034, with Japan growing at close to 4.8% CAGR; as Buscopan is a leading brand based on this API, this directly translates into expanding Buscopan API Market volumes. For example, rising incidence of functional GI disorders, greater urban stress levels, and wider access to gastroenterology clinics in East Asian and ASEAN countries are driving increased prescriptions for Buscopan, which in turn pushes API procurement contracts upward in the Buscopan API Market.

North America and emerging markets in Buscopan API Market

North America and selected emerging markets are also adding layers of growth to the Buscopan API Market, albeit from different baselines. In North America, Datavagyanik projects that hyoscine N‑butyl bromide will account for about 17.5% of global revenues by 2034, supported by a large GI patient pool and favorable reimbursement, which helps sustain brand and generic uptake linked to the Buscopan API Market. At the same time, regions such as Latin America and the Middle East & Africa are expected to maintain or slightly improve their share by 2032, as rising pharmacy penetration and growing middle-class populations fuel higher consumption of antispasmodics such as Buscopan, thereby deepening the Buscopan API Market in these territories.

Production geography and supply base in Buscopan API Market

On the supply side, the Buscopan API Market is underpinned by a concentrated but geographically diversified manufacturing footprint, ensuring both redundancy and regional specialization. For instance, platforms tracking hyoscine butylbromide list a mix of European, Indian, Chinese, and other Asian suppliers with GMP, USP, EP, and IP-compliant facilities, illustrating how the Buscopan API Market production base has shifted from a Europe-dominated originator landscape to a multi-polar, export-oriented network. Datavagyanik highlights that top 10 hyoscine N‑butyl bromide players already account for more than 55% of global value, and a significant proportion of these players are major contributors to Buscopan-focused manufacturing and long-term API supply arrangements, reinforcing the industrial depth of the Buscopan API Market.

Capacity expansion and quality orientation in Buscopan API Market

Capacity additions in Asia and disciplined optimization in Europe are reshaping production economics within the Buscopan API Market. For example, Indian manufacturers quoting hyoscine butylbromide APIs at around ₹130,000 per kg demonstrate both willingness and capability to serve international clients with high-purity material, which helps anchor competitive yet sustainable cost structures in the Buscopan API Market. At the same time, European producers continue to focus on differentiated quality, strong regulatory dossiers, and technical service, ensuring that premium-grade Buscopan API Market volumes—especially for regulated markets—remain in the hands of suppliers with proven EU‑GMP and multi-DMF track records.

Market segmentation by form and route in Buscopan API Market

From a product perspective, the Buscopan API Market is segmented along form factors such as granular, powder, and liquid, and by downstream route of administration, primarily oral and injectable. Datavagyanik points out that granular hyoscine N‑butyl bromide already represents about 40.1% of the broader HNBB segment and is growing at roughly 5.9% CAGR, faster than other forms; as Buscopan formulations increasingly use advanced granulation technologies, this accelerates demand for granular-grade material in the Buscopan API Market. For instance, oral formulations—tablets, coated tablets, and capsules—hold a majority share, with oral HNBB valued at around US$ 52.6 million in 2024 and expected to reach more than US$ 81 million by 2034, a 4.4% CAGR, underscoring how oral segment growth structurally pushes API volumes higher in the Buscopan API Market.

Segmentation by distribution channel and end customer in Buscopan API Market

The Buscopan API Market is indirectly segmented by the distribution channels through which finished Buscopan products reach patients, since channel mix influences volume stability and pricing. Hospital pharmacies accounted for about 55.2% of hyoscine N‑butyl bromide distribution in 2023, reflecting the strong institutional presence of antispasmodics in inpatient and day-care settings; this stable base underpins predictable demand for Buscopan formulations and therefore supports long-term API contracts in the Buscopan API Market. In parallel, retail and online pharmacies are expanding rapidly, especially in Asia Pacific and Latin America, and this omni-channel expansion allows Buscopan to reach self-medicating IBS and cramp patients more consistently, further broadening the downstream customer base linked to the Buscopan API Market.

Overview of Buscopan API Price landscape

Buscopan API Price is shaped by a combination of raw material costs, compliance overheads, scale efficiencies, and regional competition among qualified manufacturers. For example, listing data for hyoscine butylbromide API in India indicates per‑kilogram offers around ₹130,000 for GMP-compliant material, while international trade data compiled by specialized platforms suggest that average import/export realizations, expressed as Hyoscine Butylbromide API Price per kg, can vary substantially across lanes depending on batch size, contract length, and regulatory requirements. Datavagyanik notes that this dispersion in Buscopan API Price is typical of niche yet globally traded APIs, where a relatively small number of high-quality producers anchor the upper end of the Buscopan API Market while price-sensitive buyers source from efficient Asian plants at lower but still compliant price points.

Structural drivers of Buscopan API Price Trend

The Buscopan API Price Trend over the last few years has been moderately upward, reflecting broad-based inflation in energy, solvents, and labor, but tempered by competition and process optimization. For instance, as environmental and regulatory norms tighten, producers have had to invest in effluent treatment, solvent recovery, and advanced QC systems, all of which raise the cost base and exert gentle upward pressure on Buscopan API Price; yet, higher batch yields and better process controls in large Asian facilities have offset part of these pressures, preventing sharp spikes in the Buscopan API Price Trend. Datavagyanik expects this balanced pattern to continue, with Buscopan API Price moving within a controlled band rather than displaying the volatility seen in more commodity-like APIs, keeping the Buscopan API Market attractive for both originators and large generics planning long-term sourcing.

Regional differentials in Buscopan API Price and Buscopan API Price Trend

Regionally, Buscopan API Price differentials mirror variations in input costs, currency movements, and regulatory compliance intensity. For example, import/export analytics show that average Hyoscine Butylbromide API Price per kg in high-income markets is typically higher than in India or China, partly because shipments to tightly regulated destinations often include the cost of extensive documentation, DMF maintenance, and higher insurance, which collectively influence the Buscopan API Price Trend toward a premium band in those lanes. Conversely, buyers in price-sensitive emerging markets frequently negotiate aggressive discounts on Buscopan API Price by committing to larger annual volumes and flexible delivery windows, which creates a tiered Buscopan API Price Trend structure across geographies within the broader Buscopan API Market.

Forward-looking view on Buscopan API Price Trend and Buscopan API Market

Looking ahead, Datavagyanik anticipates that the Buscopan API Price Trend will remain broadly aligned with a 3–5% annual increase band in most regions, tracking inflation and incremental compliance costs rather than speculative swings. For instance, as the global hyoscine N‑butyl bromide market edges toward an estimated US$ 400 million overall with around 5% yearly growth, scale efficiencies will help cap unit cost escalation, allowing Buscopan API Price to inch up in a controlled manner while Buscopan API Market volumes continue to expand. In this scenario, stable Buscopan API Price Trend patterns combined with steady demand growth across Europe, Asia Pacific, and high-potential emerging markets underpin a favorable risk–return profile for both established and new suppliers participating in the Buscopan API Market.

“Buscopan API Manufacturing Database, Buscopan API Manufacturing Capacity”

• • • Buscopan API top manufacturers market share for 23+ manufacturers
    • Top 5 manufacturers and top 10 manufacturers of Buscopan API in North America, Europe, Asia Pacific
    • Production plant capacity by manufacturers and Buscopan API production data for 20+ market players
    • Buscopan API production dashboard, Buscopan API production data in excel format

Leading manufacturers anchoring Buscopan API Market

The Buscopan API Market is dominated by a core group of hyoscine butylbromide producers with strong regulatory credentials and long-standing relationships with Buscopan brand owners and large generics. Datavagyanik identifies Boehringer Ingelheim, Alchem International, ALPS Pharmaceutical Ind. Co. Ltd., Linnea SA, Alkaloid Skopje, Biotechnica Pharma Global, Nectar Lifesciences, Baxter International, Pfizer, Caleb Pharmaceuticals, and several specialized European and Asian firms as the primary industrial backbone of the Buscopan API Market. For instance, Boehringer Ingelheim not only owns the global Buscopan brand family (including Buscopan 10 mg tablets and Buscopan IBS Relief) but also maintains integrated control over a portion of upstream hyoscine butylbromide capacity, giving it a structurally large share of value within the Buscopan API Market.

Boehringer Ingelheim and Buscopan franchise in Buscopan API Market

Within the Buscopan API Market, Boehringer Ingelheim occupies a unique position as both originator of the Buscopan brand and a key controller of API demand. The company’s product lines such as Buscopan 10 mg Tablets and Buscopan IBS Relief tablets, which are indicated for abdominal cramps, IBS, and genito‑urinary spasms, rely on consistent supplies of high‑purity hyoscine butylbromide and thus drive a substantial portion of the Buscopan API Market. Datavagyanik estimates that, when originator formulations and licensed partners are combined, Boehringer Ingelheim–linked demand accounts for roughly 25–30% of the global value associated with the Buscopan API Market, although the company’s direct share of merchant API trade is lower because it is primarily a captive consumer.

Alchem International and plant-derived supply in Buscopan API Market

Alchem International is one of the most visible botanical and phytochemical API manufacturers serving the Buscopan API Market, with specialized capabilities in plant‑derived alkaloids. The company offers hyoscine butylbromide and related tropane alkaloids from FDA‑inspected and EU‑GMP‑certified facilities, positioning itself as a preferred source for regulated-market customers that require robust documentation and multi‑jurisdictional DMFs within the Buscopan API Market. For example, Alchem’s portfolio of botanical APIs for pharmaceuticals, cosmetics, and nutraceuticals gives it scale in solvent handling, extraction, and purification, and Datavagyanik expects this scale to translate into a mid‑single‑digit percentage share of global Buscopan API Market volumes, especially in high‑regulation lanes.

ALPS Pharmaceutical, Linnea and specialty producers in Buscopan API Market

Japanese-headquartered ALPS Pharmaceutical Ind. Co. Ltd. and Swiss‑based Linnea SA represent another tier of high‑quality specialty suppliers in the Buscopan API Market. Both companies are profiled as key hyoscine N‑butyl bromide manufacturers and are known for strong phytochemical and synthetic capabilities, allowing them to serve premium Buscopan formulations and bespoke hyoscine butylbromide needs for regulated markets. Datavagyanik assesses that ALPS, Linnea, and similar European and Japanese players together may account for around 15–20% of the Buscopan API Market value, leveraging their reputation for quality and technical support rather than competing purely on price.

Regional merchant suppliers in Buscopan API Market

Beyond originators and top phytochemical houses, the Buscopan API Market features a wide bench of regional merchant suppliers and traders. Platforms listing hyoscine butylbromide and hyoscine N‑butyl bromide APIs highlight companies such as LGM Pharma, Transo‑Pharm Handels GmbH, Aspen API, Fine Chemicals Corporation, Jai Radhe Sales, Tenatra Chemie/Exports, Capital Farma, Prism Industries, Remedy Labs, Rumit Group, Vital Laboratories, Zhejiang Ausun Pharmaceutical, and others as active participants in the Buscopan API Market. For example, LGM Pharma operates as a global API solutions provider and sourcing partner, while Transo‑Pharm specializes in regulated‑market distribution; together, such firms form the commercial interface that channels Buscopan API Market volumes from manufacturers to formulators worldwide.

Estimated manufacturer market shares in Buscopan API Market

While exact, audited shares are rarely disclosed, Datavagyanik synthesizes available capacity, regulatory dossier counts, and customer footprints to outline an indicative Buscopan API Market share distribution among manufacturers.

Manufacturer / cluster	Estimated share of Buscopan API Market value (indicative)
Boehringer Ingelheim–linked (captive + partners)	25–30%
Alchem International	5–8%
ALPS Pharmaceutical + Linnea SA	10–12% combined
Alkaloid Skopje + Biotechnica Pharma Global	8–10% combined
Nectar Lifesciences, Caleb, Baxter, Pfizer group	10–15% combined
Other Indian, Chinese, EU merchant suppliers	25–35% combined

These ranges reflect the broader hyoscine N‑butyl bromide landscape mapped onto Buscopan-linked demand and highlight how the Buscopan API Market remains moderately concentrated, with the top 8–10 entities controlling well over half of global value.

Product lines and positioning within Buscopan API Market

Within the Buscopan API Market, leading manufacturers differentiate themselves through specific product lines and service offerings that align with Buscopan brand and generic requirements. For instance, Boehringer Ingelheim’s Buscopan family includes Buscopan 10 mg Tablets, Buscopan IBS Relief for functional bowel disorders, and other Buscopan variants for genito‑urinary spasm relief, each demanding tightly specified hyoscine butylbromide API grades. Similarly, specialized API houses such as Alchem International, ALPS, and Linnea market pharmaceutical‑grade hyoscine butylbromide suitable for oral tablets, coated tablets, injectables, and combination products aimed at IBS, biliary colic, and renal colic segments, embedding them deeply into the Buscopan API Market’s formulation pipeline.

Strategic moves and partnerships in Buscopan API Market

Strategic collaborations and supply-chain partnerships are increasingly shaping competitive dynamics in the Buscopan API Market. For example, Datavagyanik notes that several prominent hyoscine N‑butyl bromide manufacturers—such as Alkaloid Skopje, Caleb Pharmaceuticals, Boehringer Ingelheim, ALPS, Linnea, Biotechnica Pharma Global, Alchem International, Pfizer, Nectar Lifesciences, and Baxter—are actively entering alliances to expand geographic reach, secure long‑term supply contracts, and enhance their positions across the Buscopan API Market. In practical terms, this can include co‑marketing agreements, toll manufacturing arrangements, or shared distribution platforms, enabling participants to balance capacity utilization while ensuring uninterrupted API availability for Buscopan-branded and generic products worldwide.

Recent news and industry developments in Buscopan API Market

Recent news flow underscores both growth and consolidation trends in the Buscopan API Market and its underlying hyoscine N‑butyl bromide ecosystem. In June 2024, for instance, an analysis released through major newswire channels highlighted that the global hyoscine N‑butyl bromide market—core to the Buscopan API Market—is set to surpass about US$ 87.9 million by 2032, driven by increasing gastrointestinal disorder prevalence and rising demand for granular HNBB with around 5.89% CAGR. In August 2024, a separate competitive landscape review emphasized that key players including Boehringer Ingelheim, ALPS Pharmaceutical, Biotechnica Pharma Global, Linnea, Alchem International, Alkaloid Skopje, Baxter, Pfizer, Nectar Lifesciences, and Caleb Pharmaceuticals were intensifying efforts to form strategic partnerships and improve supply‑chain management in the hyoscine N‑butyl bromide space, reinforcing their long‑term roles within the Buscopan API Market. Datavagyanik expects that, going into 2026 and beyond, these strategic moves—combined with ongoing investments in GMP upgrades and geographic expansion—will continue to consolidate market share among the top Buscopan API Market manufacturers while leaving room for efficient regional players to serve niche and cost‑sensitive demand pockets.

“Buscopan API Production Data and Buscopan API Production Trend, Buscopan API Production Database and forecast”

• • • Buscopan API production database for historical years, 12 years historical data
    • Buscopan API production data and forecast for next 8 years